Advances in nutritional management of chronic pancreatitis
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Nutrition has an important role in the management of chronic pancreatitis (CP), with two main goals for treatment of patients. The first goal is to provide optimal nutrition support and the second is to decrease pain by minimizing stimulation of the exocrine pancreas. Because cholecystokinin (CCK) stimulates secretion from the exocrine pancreas, one approach is to decrease CCK levels through modulation of diet. If postprandial pain is a limiting factor, alternative enteral therapies that minimally stimulate the pancreas may be beneficial. Nutritional counseling, antioxidants, and pancreatic enzymes may play a role in effective management of CP as well. In addition, because idiopathic CP is associated with cystic fibrosis gene mutations, therapies directed toward cystic fibrosis may also benefit these patients.
- Steer ML, Waxman I, Freedman SD: Chronic pancreatitis. N Engl J Med 1995, 332:1482–1490. CrossRef
- Pitchumoni CS: Role of nutrition in chronic pancreatitis. In Chronic Pancreatitis. Edited by Beger HG, Buchler M, Ditschuneit H, Malferleiner P. Berlin: Springer-Verlag; 1990:15–25.
- Durbec JP, Sarles H, Relationship between the relative risk of developing chronic pancreatitis and alcohol, protein and lipid consumption. Digestion 1978, 18:337–350. CrossRef
- Sarles H, Augustine P, Laugier R, et al.: Pancreatic lesions and modifications of pancreatic juice in tropical chronic pancreatitis. Dig Dis Sci 1994, 39:1337–1344. CrossRef
- Cohn JA, Friedman KJ, Silverman LM, et al.: Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med 1998, 339:653–658. CrossRef
- Whitcomb DC, Gorry MC, Preston RA, et al.: Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet 1996, 14:141–145. CrossRef
- Spannagel AW, Green GM, Guan D, et al.: Purification and characterization of a luminal cholecystokinin-releasing factor from rat intestinal secretion. Proc Natl Acad Sci U S A 1996, 93:4415–4420. CrossRef
- Go VLW, Hoffman AF, Summerskill WHJ: Pancreozymin bioassay in man based on pancreatic enzyme secretion: potency of specific amino acids and other digestive products. J Clin Invest 1970, 49:1558–1564. CrossRef
- Liddle RA, Goldfine ID, William JA. Bioassay of plasma cholecystokinin in rats: effects of food, trypsin inhibitor, and alcohol. Gastroenterology 1984, 87:542–549.
- Malagelada J-R, Go VLW, Summerskill WHJ: Different gastric, pancreatic and biliary responses to solid-liquid or homogenized meals. Dig Dis Sci 1979, 24:101–110. CrossRef
- Uden S, Acheson DW, Reeves J, et al.: Antioxidants, enzyme induction, and chronic pancreatitis: a reappraisal following studies in patients on anticonvulsants. Eur J Clin Nutr 1988, 42:561–569.
- Rose P, Fraine E, Hunt LP, et al.: Dietary antioxidants and chronic pancreatitis. Hum Nutr Clin Nutr 1986, 40:151–164.
- Braganza JM, Thomas A, Robinson A: Antioxidants to treat chronic pancreatitis in childhood? Case report and possible implications for pathogenesis. Int J Pancreatol 1988, 3:209–216.
- Freedman SD: Peptamen: a novel therapy in patients with chronic pancreatitis [abstract]. Gastroenterology 1997, 112:A267.
- Collins FS: Cystic fibrosis: molecular biology and therapeutic implications. Science 1992, 256:774–779. CrossRef
- Kerem B, Rommens JM, Buchanan JA, et al.: Identification of the cystic fibrosis gene: genetic analysis. Science 1989, 245:1073–1080. CrossRef
- Bishop M, Freedman S, Zielenski J, et al.: Does complete DNA analysis identify a higher percentage of cystic fibrosis gene mutations in patients with idiopathic chronic and recurrent acute pancreatitis [abstract]? Gastroenterology 1999, 116:A415.
- Roulet M, Frascarolo P, Rappaz I, Pilet M: Essential fatty acid deficiency in well nourished young cystic fibrosis patients. Eur J Pediatr 1997, 156:952–956. Essential fatty acid deficiencies were found in well-nourished CF patients, suggesting that this defect is not secondary to nutritional status but may be related to the CF gene defect. CrossRef
- Gilljam H, Strandvik B, Ellin A, Wiman LG: Increased mole fraction of arachidonic acid in bronchial phospholipids in patients with cystic fibrosis. Scand J Clin Lab Invest 1986, 46:511–518.
- Carlstedt-Duke J, Bronnegard M, Strandvik B: Pathological regulation of arachidonic acid release in cystic fibrosis: the putative basic defect. Proc Natl Acad Sci U S A 1986, 83:9202–9206. CrossRef
- Freedman SD, Katz M, Parker E, et al.: A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr-/- mice. Proc Natl Acad Sci U S A 1999, 96:13995–14000. A reversible fatty acid imbalance was found in CF-regulated organs from knockout mice. This abnormality was characterized by an increase in phospholipid-bound arachidonic acid and a decrease in phospholipid-bound docosahexaenoic acid in the pancreas, ileum, and lung. Correction of this lipid abnormality reversed the pathologic manifestations of CF in those organs. CrossRef
- Advances in nutritional management of chronic pancreatitis
Current Gastroenterology Reports
Volume 2, Issue 4 , pp 323-326
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links